Abiopharma

🔍 Moshkevich Solomon (Executive)

Company: Natera, Inc. (NTRA)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 405 shares of Common Stock at $206.16 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 145,295.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 560 shares of Common Stock at $200.9523 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 144,735.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 520 shares of Common Stock at $201.6004 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 144,215.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 505 shares of Common Stock at $203.3155 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 143,710.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 865 shares of Common Stock at $204.4657 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 142,845.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 400 shares of Common Stock at $205.3075 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 142,445.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 150 shares of Common Stock at $206.93 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 142,295.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
• F2: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.31 to $201.23 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.5200 to $20.6150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.81 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.17 to $205.05 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.19 to $205.56 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.